Fig. 6: The MRD stage following combination chemotherapy is associated with reduced selection pressure in immunocompromised mice. | npj Breast Cancer

Fig. 6: The MRD stage following combination chemotherapy is associated with reduced selection pressure in immunocompromised mice.

From: Enhanced bioluminescence imaging of tumor cells surviving chemotherapy in a murine model of triple-negative breast cancer

Fig. 6: The MRD stage following combination chemotherapy is associated with reduced selection pressure in immunocompromised mice.The alternative text for this image may have been generated using AI.

A Quantification of tumor cells (mCherry + ) onFACS plots of MRD tumors isolated from FVB/N (top panel, TAC(2x,q21), n = 6 pooled) and NSG (bottom panel, TAC(2x,q5), n = 6 pooled) hosts. B, C Representative microscopic images of DN, MRD, and REL B mCA-KB1P tumor tissues isolated from nude and NSG or C HmC-KB1P tumor tissues from FVB/N hosts, stained with Hematoxylin-Eosin (H&E) and for Cytokeratin 14 (CK14) and E-cadherin (E-cad) expression. Arrows mark CK14-positive tumor cells. Scale bars, 100 µm. D and E Percentage ± SEM of EpCAM positivity of mCherry+ tumor cells in DN, MRD and REL of D mCA-KB1P tumors in immunodeficient and E HmC-KB1P tumors in FVB/N mice over the TAC treatment protocol. Number of mice used for the analysis is indicated under each bar. Nude and NSG hosts were combined for this analysis (DN: nude n = 1, NSG n = 4; MRD: nude n = 4, NSG n = 4; REL: nude n = 2, NSG n = 3). #: 6 samples were pooled for a single FACS analysis. Two-way ANOVA was used for statistical analysis to compare differences between groups. Asterisks mark significant differences, **** p < 0.0001, *** p < 0.001, ** p < 0.01.

Back to article page